Oryzon Genomics receives Decision to Grant from Japanese Patent Office

Oryzon Genomics (ORYZF) announced that the Japanese Patent Office has issued a Decision to Grant for its patent application JP2021-557187, entitled “Combinations of iadademstat for cancer therapy”. Following formal grant, the patent is expected to remain in force until at least 2040, excluding any available patent term extensions. With this decision, Oryzon has now secured patent protection for these combinations in Europe, Japan, Australia and Russia, while corresponding patent applications continue to be prosecuted in other countries.